[{"id":"e726abe0-9a61-4e1d-8970-9b7613e8839f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03522142","created_at":"2021-01-18T17:20:30.581Z","updated_at":"2024-07-02T16:34:37.560Z","phase":"Phase 1","brief_title":"A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT03522142","lead_sponsor":"Incyte Corporation","biomarkers":" FLT3 • MSI • IDH1 • IDH2","pipe":" | ","alterations":" MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type","tags":["FLT3 • MSI • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB81776"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"8abb3331-04ba-4bfa-a734-5fadb9a6b09e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04458259","created_at":"2021-08-31T17:53:09.115Z","updated_at":"2024-07-02T16:35:11.509Z","phase":"Phase 1","brief_title":"Study of PF-07265807 in Participants With Metastatic Solid Tumors.","source_id_and_acronym":"NCT04458259","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • Zumrad (sasanlimab) • PF-07265807"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-03"},{"id":"48b8d938-7f8b-4bf9-a8a6-3d05476c8d31","acronym":"","url":"https://clinicaltrials.gov/study/NCT03758287","created_at":"2021-01-17T17:24:54.380Z","updated_at":"2024-07-02T16:36:08.487Z","phase":"Phase 1/2","brief_title":"Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative","source_id_and_acronym":"NCT03758287","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR T790M negative","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • ningetinib (CT053PTSA)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 07/17/2023","study_completion_date":" 07/17/2023","last_update_posted":"2022-06-22"},{"id":"0acb1841-b2e1-41a5-918e-ca85a37b180c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04946890","created_at":"2021-07-01T14:54:38.224Z","updated_at":"2024-07-02T16:36:28.403Z","phase":"Phase 1/2","brief_title":"A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04946890","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MRX2843"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2021-07-01"}]